Clinical Significance of Elevated Lipoprotein(a) in Primary and Secondary Prevention: A Multi-institutional Study

Dong-Yi Chen1,2,3, Ming-Lung Tsai4,5, Ming-Jer Hsieh1,4

  • 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan.

Insights

Elevated lipoprotein(a) [Lp(a)] levels, particularly at 30 mg/dL or higher, significantly increase the risk of major adverse cardiovascular events (MACEs). This finding holds true for individuals both with and without pre-existing atherosclerotic cardiovascular disease (ASCVD).

Area of Science:

  • Cardiology
  • Biochemistry
  • Epidemiology

Background:

  • Elevated lipoprotein(a) [Lp(a)] is increasingly recognized as a causal factor in atherosclerotic cardiovascular disease (ASCVD).
  • The specific clinical utility of Lp(a) concentration thresholds, such as 30 mg/dL, for risk stratification requires further investigation.

Purpose of the Study:

  • To investigate the association between Lp(a) concentrations and cardiovascular outcomes in a Taiwanese population.
  • To evaluate the predictive value of an Lp(a) level of 30 mg/dL for major adverse cardiovascular events (MACEs) in individuals stratified by ASCVD status.

Main Methods:

  • Retrospective analysis of 51,934 individuals from the Chang Gung Research Database (2004-2019).
  • Stratification into groups with and without established ASCVD (2,571 and 49,363 subjects, respectively).
  • Primary endpoint: MACEs, including myocardial infarction, stroke, revascularization, and cardiovascular mortality, with follow-up until December 31, 2019.

Main Results:

  • Median Lp(a) level was 9.6 mg/dL; mean follow-up was 6.6 years.
  • In ASCVD-free individuals, Lp(a) ≥30 mg/dL was linked to increased MACE risk (aSHR: 1.24; 95% CI: 1.07-1.43).
  • In the ASCVD cohort, elevated Lp(a) also predicted higher MACE occurrence (aSHR: 1.36; 95% CI: 1.07-1.74); risk increased progressively beyond 30 mg/dL.

Conclusions:

  • Lp(a) levels ≥30 mg/dL are an independent predictor of adverse cardiovascular outcomes.
  • This 30 mg/dL threshold is effective for cardiovascular risk stratification in both primary and secondary prevention settings.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
550
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
584
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
904
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K